The Role Of Host-Cell DNA Analytics In Optimizing Your Bioprocess Performance

Residual host-cell DNA (hcDNA) remains a critical quality attribute in vaccine and biologics manufacturing, with regulatory agencies emphasizing both DNA quantity and fragment size to mitigate potential safety risks. This presentation explores how advanced hcDNA analytics can support smarter bioprocess decision-making by providing rapid, reliable insights throughout development and manufacturing. A combination of qPCR- and NGS-based approaches enables sensitive quantification, fragment size assessment, and adaptation across multiple cell lines, helping teams generate actionable data that supports process optimization and regulatory compliance.

Real-world case studies demonstrate how analytical results can influence upstream and downstream process strategies, including nuclease selection, digestion times, clarification methods, and impurity management. The findings highlight that optimizing infectious titer alone may not be sufficient, as seemingly minor process changes can significantly affect hcDNA levels and overall impurity profiles. Robust assay controls also prove essential for identifying matrix effects and preventing misleading conclusions during development.

Organizations seeking to strengthen process understanding, improve product quality, and reduce development risk will gain valuable insights into the role of molecular analytics in bioprocess optimization